Search academic texts

Information × Registration Number 0222U005299, 0119U103007 , R & D reports Title Determine the role of cyclooxygenase-2 inhibitors in combination with cytostatics in radiomodification of radiation therapy for non-small cell lung and squamous cell carcinoma of the head and neck popup.stage_title Head Mitryaeva Nataliya A., Доктор біологічних наукStarenkiy Viktor P., Доктор медичних наук Registration Date 27-12-2022 Organization State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine" popup.description2 The object of study: the effectiveness of radiation therapy (RT) in combination with the COX-2 inhibitor and cisplatin in patients with non-small cell lung cancer (NSCLC) and squamous cell cancer of the head and neck (PRGН) with determination of the content of VEGF, COX-2, PGE-2 in blood serum. The aim of the work: is to increase the effectiveness of radiation therapy of non-small cell lung cancer and squamous cell carcinoma of the head and neck by radiomodification with cyclooxygenase-2 inhibitors (celecoxibs) in combination with cytostatics (cisplatin) based on determining the mechanisms of their radiosensitizing action. Methods of research and equipment: clinical, instrumental, statistical; the immunoenzymometric analyzer, the linear accelerator. Theoretical and practical results: when RT is used in combination with a COX-2 inhibitor and cisplatin in patients with NSCLC, the frequency of regressions increases by 18,9%, reaching 88,9%, annual recurrence-free survival increases by 26,6% compared to RT in combination with a COX-2 inhibitor. Local radiation reactions and hematological toxicity do not exceed II degree. Such a scheme allows improving the results of treatment due to complete regressions (40,0%) in patients with PRGН. Radiation reactions of the III degree were noted in 20,0% of cases. Novelty: it was proven for the first time that with various schemes of RT using radiomodifiers in patients with NSCLC and PRGН, there is a decrease in the level of VEGF, PGE-2 and COX-2, which indicates the strengthening of the antiangiogenic effect, which is more pronounced with the combined effect of irradiation, cisplatin and celecoxib. Recommendations have been developed for a new technology of radiation treatment by means of radiomodification with celecoxib and cisplatin in patients with NSCLC and PRGН. Effectiveness of implementation: increasing the duration of the relapse-free period and improving the quality of life of patients. Domain of usage: radiation oncology.  Product Description popup.authors Artiukh Serhii Volodymyrovych Bilozor Nataliia Volodymyrivna Bilchenko Iryna Viktorivna Grebinyk Lidiya Volodymyrivna Kolomatska Viktoriia Volodymyrivna Kondrashova Olena Ivanivna Makaruk Olena Viktorivna Potapova Tetiana Ivanivna Pshyshevska Liudmyla Anatoliivna Tkachenko Alla Anatoliivna popup.nrat_date 2022-12-27 Close